Bibliography
- NO AUTHORS LISTED: ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am. J. Health Syst. Pharm. (1999) 56(4):347-379.
- FRENKEL LM, TOBIN NH: Understanding HIV-1 drug resistance. Ther. Drug Monit. (2004) 26(2):116-121.
- PATERSON DL, SWINDELLS S, MOHR J et al.: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. (2000) 133(1):21-30.
- LUCAS GM: Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J. Antimicrob. Chemother. (2005) 55(4):413-416.
- FELLAY J, MARZOLINI C, MEADEN ER et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.
- LUBER A, GARG V, GHARAKHANIAN S et al.: Survey of medication used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART [294]. In: Seventh International Congress on Drug Therapy in HIV Infections. Glasgow, UK (2004).
- BLUM RA, SHI H, KAROL MD et al.: The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. Clin. Ther. (1997) 19(5):1013-1023.
- HATLEBAKK J: Review article: gastric acidity – comparison of esomeprazole with other proton pump inhibitors. Aliment. Pharmacol. Ther. (2003) 17(Suppl. 1):10-15.
- HORN J: Review article: understanding the pharmacodunamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Aliment. Pharmacol. Ther. Symp. (2006) 2:340-350.
- ROBINSON M, HORN J: Clinical pharmacology of proton pump inhibitors; what the practsing physician needs to know. Drugs (2003) 63:2739-2754.
- Aciphex®. Product Information. Eisai, Inc., Teaneck, NJ, USA (2003).
- MCCOLL KE, KENNERLEY P: Proton pump inhibitors – differences emerge in hepatic metabolism. Dig. Liver Dis. (2002) 34(7):461-467.
- MINER P Jr, KATZ PO, CHEN Y, SOSTEK M: Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am. J. Gastroenterol. (2003) 98(12):2616-2620.
- ROHSS K, HASSELGREN G, HEDENSTROM H: Effect of esomeprazole 40 mg versus omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig. Dis. Sci. (2002) 47(5):954-958.
- HOETELMANS R: Clinical pharmacokinetics of antiretroviral drugs. AIDS Rev. (1999) 1:167-178.
- Reyataz®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2006).
- TOMILO DL, SMITH PF, OGUNDELE AB et al.: Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers. Pharmacotherapy (2006) 26(3):341-346.
- AGARWALA S, GRAY K, WANG Y, GRASELA D: Pharmacokinetic effect of omperazole on atazanavir co-administered with ritonavir in healthy subjects. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
- KISER JJ, LICHTENSTEIN KA, ANDERSON PL, FLETCHER CV: Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy (2006) 26(4):511-514.
- KOSEL BW, STOREY SS, COLLIER AC: Lack of interaction between atazanavir and lansoprazole. AIDS (2005) 19(6):637-638.
- ANTONIOU T, YOONG D, BEIQUE L et al.: Impact of acid-suppressive therapy on virologic response to atazanavir-based regimens in antiretroviral-experienced patients: a case series. J. Acquir. Immune Defic. Syndr. (2005) 39(1):126-128.
- WINSTON A, BLOCH M, CARR A et al.: The clinical correlation’s of trough plasma atazanavir concentrations in a cohort of HIV-1 positive individuals receiving HAART. Presented at: The 12th conference on retroviruses and opportunistic infections. Boston, MA, USA (2005).
- LUBER A, BROWER R, RELOQUIN C, FRANK I: Steady state pharmacokinetics of QD fosamprenavir/ritonavir and atazanavir/ritonavir in combination with 20mg QD omperazole in healthy volunteers. Presented at: The 7th International Workshop on Clinical Pharmacology of HIV Therapy. Lisbon, Portugal (2006).
- AGARWALA S, ELAY T, CHILD M et al.: Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. 6th International Workshop on Clinical Pharmacology of HIV Therapy. Quebec City, Quebec, Canada. (2005) Abstract 11.
- O’MARA E, PILIERO P, DRUSANO G et al.: BMS-32632: a preliminary pharmacokinetic and pharmacodynamic evaluation of BMS-232632 in a protease inhibitor naïve HIV+ population. AIDS (2000) 14(Suppl.4):S19.
- TABURET AM, PC, CHAZALLON C et al.: Interactions between atazanavir/ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob. Agents Chemother. (2004) 48:2091-2096.
- AGARWALA S, RUSSO R, MUMMANENI V EA: Steady state pharmacokinetic interaction study of atazanavir with ritonavir in healthy subjects [abstract no H1716]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
- Prezista®. Product information. Tibotec, Bridgewater, NJ, USA (2006).
- SEKAR V, HOETELMANS R, DE MAREZ T, DE PAUW M et al.: Pharmacokinetics of TMC-114: effect of omeprazole and ranitidine. International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janerio, Brazil (2005).
- Lexiva®. Product information. GlaxoSmithKline, Research Triangle Park, NC, USA (2006).
- FURFINE ES, BAKER CT, HALE MR et al.: Preclinical pharmacology and pharmacokinetics of GW-433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. (2004) 48(3):791-798.
- SHELTON MJ, FORD SL, BORLAND J et al.: Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J. Acquir. Immune Defic. Syndr. (2006) 42(1):61-67.
- FORD SL, WIRE MB, LOU Y, BAKER KL, STEIN DS: Effect of antacids and ranitidine on the single-dose pharmacokinetics of fosamprenavir. Antimicrob. Agents Chemother. (2005) 49(1):467-469.
- Crixivan®. Product information. Merck & Co., Inc., Whitehouse Station, NJ, USA (2004).
- BURGER DM, HUGEN PW, KROON FP et al.: Pharmacokinetic interaction between the proton pump inhibitor omeprazole and the HIV protease inhibitor indinavir. AIDS (1998) 12(15):2080-2082.
- LIN JH, CHEN IW, VASTAG KJ, OSTOVIC D: pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. (1995) 23(7):730-735.
- Videx®. Product information. Bristol-Myers Squibb, Princeton, NJ, USA (2000).
- BERTZ R, CHIU Y, NAYLOR C, LUFF K, BRUN S: Lack of effect of gastric acid reducing agents on lopinavir/ritonavir plasma concentrations in HIV-infected patients. Presented at: The 7th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (2004).
- Kaletra®. Product information. Abbott Laboratories, North Chicago, IL, USA.
- KLEIN C, CHIU Y, CAI Y et al.: Lack of effect of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir Tablet. Presented at: The 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA (2006).
- Invirase®. Product information. Roche Laboratories, Inc., Nutley, NJ, USA (2005).
- WINSTON A, BACK D, FLETCHER C et al.: Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS (2006) 20(10):1401-1406.
- KAKUDA TN, FALCON RW: Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy (2006) 26(8):1060-1068.
- Aptivus®. Product information. Boehringer Ingelheim, Ridgefield, CT, USA (2006).
- HEESWIJK REA: The pharmacokinetic interactions between tipranavir/ritonavir 500 mg/200 mg bid (TPV/r) and atorvastatin, antacid and CYP 3A4 in healthy volunteers. Presented at: The 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy (2004).
- Rescriptor®. Product information. Pfizer, Groton, CT, USA (2006).
- SHELTON MJ, HEWITT RG, ADAMS JM et al.: Delavirdine malabsorption in HIV-infected subjects with spontaneous gastric hypoacidity. J. Clin. Pharmacol. (2003) 43(2):171-179.
- LAKE-BAKAAR G, QUADROS E, BEIDAS S et al.: Gastric secretory failure in patients with the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. (1988) 109(6):502-504.
- WELAGE LS, CARVER PL, REVANKAR S, PIERSON C, KAUFFMAN CA: Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin. Infect. Dis. (1995) 21(6):1431-1438.
- SHELTON MJ, ADAMS JM, HEWITT RG, MORSE GD: Previous infection with Helicobacter pylori is the primary determinant of spontaneous gastric hypoacidity in human immunodeficiency virus-infected outpatients. Clin. Infect. Dis. (1998) 27(4):739-745.
- SHAFFER RT, LAHATTE LJ, KELLY JW et al.: Gastric acid secretion in HIV-1 infection. Am. J. Gastroenterol. (1992) 87(12):1777-1780.
- OLMOS M, ARAYA V, PSKORZ E et al.: Coinfection: Helicobacter pylori/human immunodeficiency virus. Dig. Dis. Sci. (2004) 49(11-12):1836-1839.
- PISCATELLI S, BAEDE P, DEGIER K, VAN ‘T KLOOSTER G, GRAHAM N: Pharmacokinetics of TMC-125 in HIV infected patients and healthy volunteers. 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC, USA April (2002).
- GRUZDEV B, RAKHMANOVA A, DOUBOVSKAYA E et al.: A randomized, double-blind, placebo-controlled trial of TMC-125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS (2003) 17(17):2487-2494.
- GYURE-SCHOLLER M EA: TMC-125 bioavailability is not affected by ranitidine and omeprazole. International AIDS Society. Toronto, Canada (2006).
- BACK D, GATTI G, FLETCHER C et al.: Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS (2002) 16(Suppl. 1):S5-S37.
- GERBER JG, ACOSTA EP: Therapeutic drug monitoring in the treatment of HIV infection. J. Clin. Virol. (2003) 27(2):117-128.
- CLEVENBERGH P, MOULY S, SELLIER P et al.: Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinicians point of view. Curr. HIV Res. (2004) 2:309-321.
- FELLAY J, MARZOLINI C, MEADEN ER et al.: Repsonse to antiretroviral treatment in HIV-1 infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet (2002) 359(9300):30-36.
Website
- http://AIDSinfo.nih.govPanel on Antiretroviral Guidelines for Adults and Adolescents: Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online] (last accessed March 2007).